<DOC>
	<DOC>NCT01344304</DOC>
	<brief_summary>The object of this study is to evaluate the superiority of aprepitant therapy with a 5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a 5HT3-receptor antagonist and dexamethasone for prevention of nausea and vomiting in first course chemotherapy.</brief_summary>
	<brief_title>Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age: ≥20 years old Sex: Not specified Patients with colon/rectal cancer who first underwent FOLFOX, XELOX or SOX regimen including oxaliplatin at ≥85 mg/m2 (naive patient), or those who had already started chemotherapy and had nausea of Grade 2 or higher in the last course or an earlier course (nonnaive patient). Stage: not specified (neoadjuvant/adjuvant chemotherapy, advanced or recurrent type are allowed) Combination of molecular targeted therapy: allowable Written informed consent for participation in the study. Severe liver or kidney disease Nausea/vomiting within 24 hr prior to chemotherapy. Treatment with antiemetics within 24 hr prior to chemotherapy. Presence of factors causing nausea/vomiting other than chemotherapy (e.g. brain tumor, gastrointestinal obstruction, active peptic ulcer disease, brain metastasis) Presence of a disease precluding 3day administration of dexamethasone (e.g. uncontrollable diabetes) Pregnant or lactating women, women who plan to become pregnant. Current treatment with pimozide. Any patient judged to be inappropriate for the study by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>aprepitant therapy</keyword>
	<keyword>fosaprepitant therapy</keyword>
	<keyword>5HT3-receptor antagonist</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>XELOX</keyword>
	<keyword>SOX</keyword>
</DOC>